-
Company Insights
New![]()
Innovation and Patenting activity of CTI BioPharma Corp Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of CTI BioPharma Corp Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Sleep Apnea Clinical Trials Overview The Sleep Apnea clinical trial report consists of 613 trials. The report provides an overview of the Sleep Apnea clinical trial scenario. The report provides top-line data relating to the clinical trials on Sleep Apnea. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Belvarafenib in Metastatic Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Belvarafenib in Metastatic Melanoma Drug Details: Belvarafenib is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CGX-1321 in Esophageal Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CGX-1321 in Esophageal Cancer Drug Details: CGX-1321 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TCN-201 in Synovial Sarcoma
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TCN-201 in Synovial Sarcoma Drug Details: TCN-201 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Isunakinra in Bile Duct Cancer (Cholangiocarcinoma)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Isunakinra in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Isunakinra (EBI-005) was under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KITE-222 in Primary Mediastinal B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KITE-222 in Primary Mediastinal B-Cell Lymphoma Drug Details: KITE-222 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Naptumomab Estafenatox in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Naptumomab Estafenatox in Metastatic Ovarian Cancer Drug Details:ABR-217620 (anyara, naptumomab estafenatox) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pacritinib in Chronic Myelomonocytic Leukemia (CMML)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pacritinib in Chronic Myelomonocytic Leukemia (CMML) Drug Details: PacritInib (Vonjo) is an anti neoplastic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brexucabtagene autoleucel in Chronic Lymphocytic Leukemia (CLL)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brexucabtagene autoleucel in Chronic Lymphocytic Leukemia (CLL) Drug Details: Brexucabtagene Autoleucel (Tecartus) is a...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.